174 related articles for article (PubMed ID: 35136230)
1. Approvals in 2021: dangling Accelerated Approvals, drug dosing, new approvals and beyond.
Lemery S; Pazdur R
Nat Rev Clin Oncol; 2022 Apr; 19(4):217-218. PubMed ID: 35136230
[TBL] [Abstract][Full Text] [Related]
2. "Dangling" Accelerated Approvals in Oncology.
Beaver JA; Pazdur R
N Engl J Med; 2021 May; 384(18):e68. PubMed ID: 33882220
[No Abstract] [Full Text] [Related]
3. New Indications and Approvals for Anticancer Drugs.
Aschenbrenner DS
Am J Nurs; 2021 Dec; 121(12):16-17. PubMed ID: 34792500
[TBL] [Abstract][Full Text] [Related]
4. Single-arm trials for US Food and Drug Administration cancer drug approvals: Although there are some challenges in using single-arm studies for accelerated drug approvals, it can make a difference in getting drugs previously approved for other uses to patients.: Although there are some challenges in using single-arm studies for accelerated drug approvals, it can make a difference in getting drugs previously approved for other uses to patients.
Nierengarten MB
Cancer; 2023 Jun; 129(11):1626. PubMed ID: 37158643
[No Abstract] [Full Text] [Related]
5. Study bolsters concerns about US FDA accelerated drug approvals.
Furlow B
Lancet Oncol; 2024 May; 25(5):543. PubMed ID: 38621403
[No Abstract] [Full Text] [Related]
6. Comparison of FDA accelerated vs regular pathway approvals for lung cancer treatments between 2006 and 2018.
Ribeiro TB; Buss L; Wayant C; Nobre MRC
PLoS One; 2020; 15(7):e0236345. PubMed ID: 32706800
[TBL] [Abstract][Full Text] [Related]
7. Use of multiple endpoints and approval paths depicts a decade of FDA oncology drug approvals.
Shea MB; Roberts SA; Walrath JC; Allen JD; Sigal EV
Clin Cancer Res; 2013 Jul; 19(14):3722-31. PubMed ID: 23665737
[TBL] [Abstract][Full Text] [Related]
8. Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration.
Hilal T; Sonbol MB; Prasad V
JAMA Oncol; 2019 Jun; 5(6):887-892. PubMed ID: 31046071
[TBL] [Abstract][Full Text] [Related]
9. FDA new drug approvals in Q1 2021.
Urquhart L
Nat Rev Drug Discov; 2021 May; 20(5):334. PubMed ID: 33854219
[No Abstract] [Full Text] [Related]
10. Accelerated approvals hit the target in precision oncology.
Subbiah V; Wirth LJ; Kurzrock R; Pazdur R; Beaver JA; Singh H; Mehta GU
Nat Med; 2022 Oct; 28(10):1976-1979. PubMed ID: 36192554
[No Abstract] [Full Text] [Related]
11. New drug approvals for prostate cancer.
Tannock IF
Clin Adv Hematol Oncol; 2024 Jun; 22(5):245-246. PubMed ID: 38805317
[No Abstract] [Full Text] [Related]
12. Inappropriate use of progression-free survival in cancer drug approvals.
Naci H; Davis C
BMJ; 2020 Mar; 368():m770. PubMed ID: 32156802
[No Abstract] [Full Text] [Related]
13. Anticancer Drug Approvals in the Past Decade-Quality vs Quantity.
Chakraborty R
JAMA Netw Open; 2021 Dec; 4(12):e2139178. PubMed ID: 34905012
[No Abstract] [Full Text] [Related]
14. 2011 FDA drug approvals.
Mullard A
Nat Rev Drug Discov; 2012 Feb; 11(2):91-4. PubMed ID: 22293555
[No Abstract] [Full Text] [Related]
15. U.S. Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer.
Ribeiro TB; Ribeiro A; Rodrigues LO; Harada G; Nobre MRC
Int J Technol Assess Health Care; 2020; 36(1):20-28. PubMed ID: 31775939
[TBL] [Abstract][Full Text] [Related]
16. Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival: An Analysis of 5 Years of US Food and Drug Administration Approvals.
Kim C; Prasad V
JAMA Intern Med; 2015 Dec; 175(12):1992-4. PubMed ID: 26502403
[No Abstract] [Full Text] [Related]
17. Oncology approvals in 2020: a year of firsts in the midst of a pandemic.
Amiri-Kordestani L; Pazdur R
Nat Rev Clin Oncol; 2021 Mar; 18(3):129-130. PubMed ID: 33514911
[TBL] [Abstract][Full Text] [Related]
18. Fragility of randomized trials supporting cancer drug approvals stratified by approval pathway and review designations.
Wilson BE; Desnoyers A; Nadler MB; Tibau A; Amir E
Cancer Med; 2021 Aug; 10(16):5405-5414. PubMed ID: 34323019
[TBL] [Abstract][Full Text] [Related]
19. Rare cancer trial design: lessons from FDA approvals.
Gaddipati H; Liu K; Pariser A; Pazdur R
Clin Cancer Res; 2012 Oct; 18(19):5172-8. PubMed ID: 22718862
[TBL] [Abstract][Full Text] [Related]
20. End points and United States Food and Drug Administration approval of oncology drugs.
Johnson JR; Williams G; Pazdur R
J Clin Oncol; 2003 Apr; 21(7):1404-11. PubMed ID: 12663734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]